Thermochemotherapy for melanoma metastases in liver

F. K. Storm, L. R. Kaiser, James E Goodnight Jr, W. H. Harrison, R. S. Elliott, A. S. Gomes, D. L. Morton

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Metastatic melanoma in the liver has carried an extremely poor prognosis regardless of therapy. Because transient responses (1/6 disease regressions and 2/6 disease stabilizations for four months) in selected patients treated with intraarterial (IA) (DTIC infusion were encouraging and because localized hyperthermia may be both tumoricidal and synergistic with chemotherapy, these modalities were combined for treatment of patients with advanced liver metastases. Of 10 patients treated with IA-DTIC plus heat, three (30%) had disease regression and five (50%) had disease stabilization for 3-14 months (median 6.5 months) and survived 3.5-18 months (median 8.5 months). During treatment, 4/5 patients had pain relief and 7/10 retained or acquired normal activities. Myelosuppression was minimal and no hyperthermia toxicity occurred. A retrospective review of 10 patients with similar disease levels who were treated with conventional intravenous (IV)-DTIC indicated no responses, and no responses were seen in five patients treated with IV-DTIC plus heat. However, this latter group may have been selected patients due to the inability to place a percutaneous hepatic artery infusion catheter. This pilot study suggests that combination IA-DTIC and hyperthermia has a high response rate, is safe, and can provide quality survival for many patients.

Original languageEnglish (US)
Pages (from-to)1243-1248
Number of pages6
JournalCancer
Volume49
Issue number6
StatePublished - 1982

Fingerprint

Melanoma
Dacarbazine
Neoplasm Metastasis
Liver
Fever
Hot Temperature
Intra Arterial Infusions
Hepatic Artery
Therapeutics
Catheters
Drug Therapy
Pain
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Storm, F. K., Kaiser, L. R., Goodnight Jr, J. E., Harrison, W. H., Elliott, R. S., Gomes, A. S., & Morton, D. L. (1982). Thermochemotherapy for melanoma metastases in liver. Cancer, 49(6), 1243-1248.

Thermochemotherapy for melanoma metastases in liver. / Storm, F. K.; Kaiser, L. R.; Goodnight Jr, James E; Harrison, W. H.; Elliott, R. S.; Gomes, A. S.; Morton, D. L.

In: Cancer, Vol. 49, No. 6, 1982, p. 1243-1248.

Research output: Contribution to journalArticle

Storm, FK, Kaiser, LR, Goodnight Jr, JE, Harrison, WH, Elliott, RS, Gomes, AS & Morton, DL 1982, 'Thermochemotherapy for melanoma metastases in liver', Cancer, vol. 49, no. 6, pp. 1243-1248.
Storm FK, Kaiser LR, Goodnight Jr JE, Harrison WH, Elliott RS, Gomes AS et al. Thermochemotherapy for melanoma metastases in liver. Cancer. 1982;49(6):1243-1248.
Storm, F. K. ; Kaiser, L. R. ; Goodnight Jr, James E ; Harrison, W. H. ; Elliott, R. S. ; Gomes, A. S. ; Morton, D. L. / Thermochemotherapy for melanoma metastases in liver. In: Cancer. 1982 ; Vol. 49, No. 6. pp. 1243-1248.
@article{a64583ee288f4001ab7fa522bff96e97,
title = "Thermochemotherapy for melanoma metastases in liver",
abstract = "Metastatic melanoma in the liver has carried an extremely poor prognosis regardless of therapy. Because transient responses (1/6 disease regressions and 2/6 disease stabilizations for four months) in selected patients treated with intraarterial (IA) (DTIC infusion were encouraging and because localized hyperthermia may be both tumoricidal and synergistic with chemotherapy, these modalities were combined for treatment of patients with advanced liver metastases. Of 10 patients treated with IA-DTIC plus heat, three (30{\%}) had disease regression and five (50{\%}) had disease stabilization for 3-14 months (median 6.5 months) and survived 3.5-18 months (median 8.5 months). During treatment, 4/5 patients had pain relief and 7/10 retained or acquired normal activities. Myelosuppression was minimal and no hyperthermia toxicity occurred. A retrospective review of 10 patients with similar disease levels who were treated with conventional intravenous (IV)-DTIC indicated no responses, and no responses were seen in five patients treated with IV-DTIC plus heat. However, this latter group may have been selected patients due to the inability to place a percutaneous hepatic artery infusion catheter. This pilot study suggests that combination IA-DTIC and hyperthermia has a high response rate, is safe, and can provide quality survival for many patients.",
author = "Storm, {F. K.} and Kaiser, {L. R.} and {Goodnight Jr}, {James E} and Harrison, {W. H.} and Elliott, {R. S.} and Gomes, {A. S.} and Morton, {D. L.}",
year = "1982",
language = "English (US)",
volume = "49",
pages = "1243--1248",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Thermochemotherapy for melanoma metastases in liver

AU - Storm, F. K.

AU - Kaiser, L. R.

AU - Goodnight Jr, James E

AU - Harrison, W. H.

AU - Elliott, R. S.

AU - Gomes, A. S.

AU - Morton, D. L.

PY - 1982

Y1 - 1982

N2 - Metastatic melanoma in the liver has carried an extremely poor prognosis regardless of therapy. Because transient responses (1/6 disease regressions and 2/6 disease stabilizations for four months) in selected patients treated with intraarterial (IA) (DTIC infusion were encouraging and because localized hyperthermia may be both tumoricidal and synergistic with chemotherapy, these modalities were combined for treatment of patients with advanced liver metastases. Of 10 patients treated with IA-DTIC plus heat, three (30%) had disease regression and five (50%) had disease stabilization for 3-14 months (median 6.5 months) and survived 3.5-18 months (median 8.5 months). During treatment, 4/5 patients had pain relief and 7/10 retained or acquired normal activities. Myelosuppression was minimal and no hyperthermia toxicity occurred. A retrospective review of 10 patients with similar disease levels who were treated with conventional intravenous (IV)-DTIC indicated no responses, and no responses were seen in five patients treated with IV-DTIC plus heat. However, this latter group may have been selected patients due to the inability to place a percutaneous hepatic artery infusion catheter. This pilot study suggests that combination IA-DTIC and hyperthermia has a high response rate, is safe, and can provide quality survival for many patients.

AB - Metastatic melanoma in the liver has carried an extremely poor prognosis regardless of therapy. Because transient responses (1/6 disease regressions and 2/6 disease stabilizations for four months) in selected patients treated with intraarterial (IA) (DTIC infusion were encouraging and because localized hyperthermia may be both tumoricidal and synergistic with chemotherapy, these modalities were combined for treatment of patients with advanced liver metastases. Of 10 patients treated with IA-DTIC plus heat, three (30%) had disease regression and five (50%) had disease stabilization for 3-14 months (median 6.5 months) and survived 3.5-18 months (median 8.5 months). During treatment, 4/5 patients had pain relief and 7/10 retained or acquired normal activities. Myelosuppression was minimal and no hyperthermia toxicity occurred. A retrospective review of 10 patients with similar disease levels who were treated with conventional intravenous (IV)-DTIC indicated no responses, and no responses were seen in five patients treated with IV-DTIC plus heat. However, this latter group may have been selected patients due to the inability to place a percutaneous hepatic artery infusion catheter. This pilot study suggests that combination IA-DTIC and hyperthermia has a high response rate, is safe, and can provide quality survival for many patients.

UR - http://www.scopus.com/inward/record.url?scp=0020061352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020061352&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 1243

EP - 1248

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -